Sino Biopharmaceutical Limited (HKG:1177)

United States Steel Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	28,866	26,199	26,026	26,861	23,647
Revenue Growth (YoY)	10.18%	0.67%	-3.11%	13.59%	-2.42%
Cost of Revenue	5,336	4,990	4,488	5,332	5,182
Gross Profit	23,530	21,210	21,539	21,529	18,465
Selling, General & Admin	12,159	11,067	11,709	12,704	11,629
Other Operating Expenses	5,569	4,704	4,444	4,193	2,738
Operating Expenses	17,729	15,770	16,153	16,896	14,366
Operating Income	5,801	5,439	5,386	4,633	4,098
Interest Expense	-295.12	-495.24	-429.49	-308.62	-323.37
Interest & Investment Income	1,347	611.38	472.38	559.89	520.28
Earnings From Equity Investments	-118.3	-525.71	-152.98	13,631	-3.23
Currency Exchange Gain (Loss)	-123.41	-96.02	138.22	292.3	-
Other Non Operating Income (Expenses)	359.43	570.2	185.84	488.2	272.92
EBT Excluding Unusual Items	6,971	5,504	5,600	19,295	4,565
Impairment of Goodwill	-18.62	-	-	-	-
Gain (Loss) on Sale of Investments	-1,483	-46.9	-449.08	-265.38	443.44
Gain (Loss) on Sale of Assets	163.47	57.02	3.47	-4.28	4.58
Asset Writedown	-286.81	-	-19.4	-441.1	-
Other Unusual Items	-68.09	-104.06	80.08	-12.02	-
Pretax Income	5,277	5,410	5,215	18,573	5,013
Income Tax Expense	492.92	797.27	696.72	1,958	672.38
Earnings From Continuing Operations	4,785	4,613	4,518	16,615	4,341
Earnings From Discontinued Operations	1,580	484.76	484.47	-	-
Net Income to Company	6,365	5,097	5,003	16,615	4,341
Minority Interest in Earnings	-2,865	-2,765	-2,459	-2,006	-1,570
Net Income	3,500	2,332	2,544	14,608	2,771
Net Income to Common	3,500	2,332	2,544	14,608	2,771
Net Income Growth	50.08%	-8.32%	-82.59%	427.17%	0.35%
Shares Outstanding (Basic)	18,294	18,529	18,622	18,769	18,800
Shares Outstanding (Diluted)	18,295	18,529	19,017	19,283	18,800
Shares Change (YoY)	-1.26%	-2.57%	-1.38%	2.57%	-0.06%
EPS (Basic)	0.19	0.13	0.14	0.78	0.15
EPS (Diluted)	0.19	0.13	0.12	0.73	0.15
EPS Growth	51.97%	3.55%	-83.41%	397.00%	0.40%
Free Cash Flow	5,655	4,998	5,022	3,652	3,901
Free Cash Flow Per Share	0.31	0.27	0.26	0.19	0.21
Dividend Per Share	0.065	0.044	0.106	0.065	0.062
Dividend Growth	46.97%	-58.16%	62.87%	5.59%	29.39%
Gross Margin	81.51%	80.95%	82.76%	80.15%	78.09%
Operating Margin	20.10%	20.76%	20.69%	17.25%	17.33%
Profit Margin	12.12%	8.90%	9.77%	54.38%	11.72%
Free Cash Flow Margin	19.59%	19.08%	19.30%	13.60%	16.50%
EBITDA	6,893	6,379	6,254	5,453	5,661
EBITDA Margin	23.88%	24.35%	24.03%	20.30%	23.94%
D&A For EBITDA	1,092	939.85	868.56	820.57	1,562
EBIT	5,801	5,439	5,386	4,633	4,098
EBIT Margin	20.10%	20.76%	20.69%	17.25%	17.33%
Effective Tax Rate	9.34%	14.74%	13.36%	10.54%	13.41%

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.